Anthera Pharmaceuticals Announces Presentation at Healthcare Conferences, ACR Reception and Timing of Third Quarter Financial...
October 28 2015 - 3:03PM
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced
the Company’s attendance at the following healthcare conferences:
- November 4th, 2015, Mr. Paul F. Truex, President and Chief
Executive Officer, will host one-on-one meetings at the 2015 Citi
Global Healthcare Conference at the Palace Hotel in New
York.
- November 6th, 2015, Anthera will report its third quarter 2015
financial and operational results after the close of the
market.
- November 9th, 2015 from 7:00 to 9:00 PM during the American
College of Rheumatology Annual Meeting, Anthera will host a
reception to discuss the CHABLIS program with blisibimod. The
reception will be held at the Press Club, 20 Yerba Buena Lane, San
Francisco, California. To receive an invitation to the event,
please contact Nikhil Agarwal at nagarwal@anthera.com, prior to
Wednesday, November 4th, 2015.
- November 19th, 2015, Dr. Colin Hislop, will present a corporate
update at the Jefferies 2015 Autumn Global Healthcare Conference at
the May Fair Hotel in London, United Kingdom.
- December 1st and 2nd, 2015, Mr. Paul F. Truex will present a
corporate update at the 2015 Annual Piper Jaffray Healthcare
Conference at the Palace Hotel in New York.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused
on developing and commercializing products to treat serious and
life-threatening diseases, including lupus, lupus with
glomerulonephritis, IgA nephropathy, and exocrine pancreatic
insufficiency due to cystic fibrosis. Additional information on the
Company can be found at www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include statements about
Anthera's expectations with respect to its public offering,
including statements about its intended use of proceeds from
the offering. Such statements are based on
Anthera's expectations as of the date of this press release
and are subject to certain risks and uncertainties that could cause
actual results to differ materially, including but not limited to
those set forth in Anthera's public filings with the SEC,
including Anthera's Quarterly Report on Form 10-Q for the quarter
ended June 30, 2015. Anthera disclaims any intent or
obligation to update any forward-looking statements, whether
because of new information, future events or otherwise, except as
required by applicable law.
CONTACT: Nikhil Agarwal of Anthera Pharmaceuticals, Inc.
nagarwal@anthera.com or 510-856-5600x5621
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Apr 2023 to Apr 2024